Healthcare resource use of patients with transthyretin amyloid cardiomyopathy
Abstract Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is the cardiac manifestation of transthyretin amyloidosis (ATTR). The aim of this study was to estimate healthcare resource use for ATTR‐CM patients compared with heart failure (HF) patients, in Denmark, Finland, Norway, and Sweden. Method...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | ESC Heart Failure |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ehf2.13913 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832540319259820032 |
|---|---|
| author | Rosa Lauppe Johan Liseth Hansen Anna Fornwall Katarina Johansson Mark H. Rozenbaum Anne Mette Strand Merja Vakevainen Johanna Kuusisto Einar Gude J. Gustav Smith Finn Gustafsson |
| author_facet | Rosa Lauppe Johan Liseth Hansen Anna Fornwall Katarina Johansson Mark H. Rozenbaum Anne Mette Strand Merja Vakevainen Johanna Kuusisto Einar Gude J. Gustav Smith Finn Gustafsson |
| author_sort | Rosa Lauppe |
| collection | DOAJ |
| description | Abstract Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is the cardiac manifestation of transthyretin amyloidosis (ATTR). The aim of this study was to estimate healthcare resource use for ATTR‐CM patients compared with heart failure (HF) patients, in Denmark, Finland, Norway, and Sweden. Methods and results Data from nationwide healthcare registers in the four countries were used. ATTR‐CM patients were defined as individuals diagnosed with amyloidosis and cardiomyopathy or HF between 2008 and 2018. Patients in the ATTR‐CM cohort were matched to patients with HF but without ATTR‐CM diagnosis. Resource use included number of visits to specialty outpatient and inpatient hospital care. A total of 1831 ATTR‐CM and 1831 HF patients were included in the analysis. The mean number of hospital‐based healthcare contacts increased in both the ATTR‐CM and HF cohort during 3 years pre‐diagnosis and was consistently higher for the ATTR‐CM cohort compared with the HF cohort, with 6.1 [CI: 5.9–6.3] vs. 3.2 [CI: 3.1–3.3] outpatient visits and 1.03 [CI: 0.96–1.1] vs. 0.7 [CI: 0.7–0.8] hospitalizations. In the first year following diagnosis, patients with ATTR‐CM continued to visit outpatient care (10.2 [CI: 10.1, 10.4] vs. 5.7 [CI: 5.6, 5.9]) and were admitted to hospital more frequently (3.3 [CI: 3.2, 3.4] vs. 2.5 [CI: 2.5, 2.6]) than HF patients. Conclusions Transthyretin amyloid cardiomyopathy imposes a high burden on healthcare systems with twice as many outpatient specialist visits and 50% more hospitalizations in the year after diagnosis compared with HF patients without ATTR‐CM. Studies to investigate if earlier diagnosis and treatment of ATTR‐CM may lower resource use are warranted. |
| format | Article |
| id | doaj-art-5657360f98a44d59b83d238ed1ae8f3a |
| institution | Kabale University |
| issn | 2055-5822 |
| language | English |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | ESC Heart Failure |
| spelling | doaj-art-5657360f98a44d59b83d238ed1ae8f3a2025-02-05T05:22:10ZengWileyESC Heart Failure2055-58222022-06-01931636164210.1002/ehf2.13913Healthcare resource use of patients with transthyretin amyloid cardiomyopathyRosa Lauppe0Johan Liseth Hansen1Anna Fornwall2Katarina Johansson3Mark H. Rozenbaum4Anne Mette Strand5Merja Vakevainen6Johanna Kuusisto7Einar Gude8J. Gustav Smith9Finn Gustafsson10Quantify Research AB Stockholm 112 21 SwedenQuantify Research AB Stockholm 112 21 SwedenQuantify Research AB Stockholm 112 21 SwedenPfizer AB Stockholm SwedenPfizer, Inc. Capelle aan den IJssel The NetherlandsPfizer Denmark ApS Ballerup DenmarkPfizer Oy Helsinki FinlandDepartment of Medicine and Clinical Research Kuopio University Hospital and University of Eastern Finland Kuopio FinlandDepartment of Cardiology Oslo University Hospital Rikshospitalet Oslo NorwayDepartment of Cardiology, Wallenberg Center for Molecular Medicine and Lund University Diabetes Center, Clinical Sciences Lund University and Skåne University Hospital Lund SwedenDepartment of Cardiology Rigshospitalet Copenhagen DenmarkAbstract Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is the cardiac manifestation of transthyretin amyloidosis (ATTR). The aim of this study was to estimate healthcare resource use for ATTR‐CM patients compared with heart failure (HF) patients, in Denmark, Finland, Norway, and Sweden. Methods and results Data from nationwide healthcare registers in the four countries were used. ATTR‐CM patients were defined as individuals diagnosed with amyloidosis and cardiomyopathy or HF between 2008 and 2018. Patients in the ATTR‐CM cohort were matched to patients with HF but without ATTR‐CM diagnosis. Resource use included number of visits to specialty outpatient and inpatient hospital care. A total of 1831 ATTR‐CM and 1831 HF patients were included in the analysis. The mean number of hospital‐based healthcare contacts increased in both the ATTR‐CM and HF cohort during 3 years pre‐diagnosis and was consistently higher for the ATTR‐CM cohort compared with the HF cohort, with 6.1 [CI: 5.9–6.3] vs. 3.2 [CI: 3.1–3.3] outpatient visits and 1.03 [CI: 0.96–1.1] vs. 0.7 [CI: 0.7–0.8] hospitalizations. In the first year following diagnosis, patients with ATTR‐CM continued to visit outpatient care (10.2 [CI: 10.1, 10.4] vs. 5.7 [CI: 5.6, 5.9]) and were admitted to hospital more frequently (3.3 [CI: 3.2, 3.4] vs. 2.5 [CI: 2.5, 2.6]) than HF patients. Conclusions Transthyretin amyloid cardiomyopathy imposes a high burden on healthcare systems with twice as many outpatient specialist visits and 50% more hospitalizations in the year after diagnosis compared with HF patients without ATTR‐CM. Studies to investigate if earlier diagnosis and treatment of ATTR‐CM may lower resource use are warranted.https://doi.org/10.1002/ehf2.13913TTR amyloidosisHealthcare resource useBurdenHeart failureCardiomyopathy |
| spellingShingle | Rosa Lauppe Johan Liseth Hansen Anna Fornwall Katarina Johansson Mark H. Rozenbaum Anne Mette Strand Merja Vakevainen Johanna Kuusisto Einar Gude J. Gustav Smith Finn Gustafsson Healthcare resource use of patients with transthyretin amyloid cardiomyopathy ESC Heart Failure TTR amyloidosis Healthcare resource use Burden Heart failure Cardiomyopathy |
| title | Healthcare resource use of patients with transthyretin amyloid cardiomyopathy |
| title_full | Healthcare resource use of patients with transthyretin amyloid cardiomyopathy |
| title_fullStr | Healthcare resource use of patients with transthyretin amyloid cardiomyopathy |
| title_full_unstemmed | Healthcare resource use of patients with transthyretin amyloid cardiomyopathy |
| title_short | Healthcare resource use of patients with transthyretin amyloid cardiomyopathy |
| title_sort | healthcare resource use of patients with transthyretin amyloid cardiomyopathy |
| topic | TTR amyloidosis Healthcare resource use Burden Heart failure Cardiomyopathy |
| url | https://doi.org/10.1002/ehf2.13913 |
| work_keys_str_mv | AT rosalauppe healthcareresourceuseofpatientswithtransthyretinamyloidcardiomyopathy AT johanlisethhansen healthcareresourceuseofpatientswithtransthyretinamyloidcardiomyopathy AT annafornwall healthcareresourceuseofpatientswithtransthyretinamyloidcardiomyopathy AT katarinajohansson healthcareresourceuseofpatientswithtransthyretinamyloidcardiomyopathy AT markhrozenbaum healthcareresourceuseofpatientswithtransthyretinamyloidcardiomyopathy AT annemettestrand healthcareresourceuseofpatientswithtransthyretinamyloidcardiomyopathy AT merjavakevainen healthcareresourceuseofpatientswithtransthyretinamyloidcardiomyopathy AT johannakuusisto healthcareresourceuseofpatientswithtransthyretinamyloidcardiomyopathy AT einargude healthcareresourceuseofpatientswithtransthyretinamyloidcardiomyopathy AT jgustavsmith healthcareresourceuseofpatientswithtransthyretinamyloidcardiomyopathy AT finngustafsson healthcareresourceuseofpatientswithtransthyretinamyloidcardiomyopathy |